Get the Stockscreener App
97.44
1.32%
1.27
Pre-market:
98.01
0.57
+0.58%
Zimmer Biomet Holdings Inc stock is traded at $97.44, with a volume of 1.43M.
It is up +1.32% in the last 24 hours and down -12.00% over the past month.
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two thirds of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.
See More
Previous Close:
$96.17
Open:
$96.95
24h Volume:
1.43M
Relative Volume:
0.73
Market Cap:
$19.84B
Revenue:
$7.68B
Net Income/Loss:
$903.80M
P/E Ratio:
21.90
EPS:
4.45
Net Cash Flow:
$1.14B
1W Performance:
+0.17%
1M Performance:
-12.00%
6M Performance:
-6.54%
1Y Performance:
-19.32%
1-Day Range:
$95.84
$97.65
1-Week Range:
$93.10
$98.71
52-Week Range:
$93.10
$123.96
Zimmer Biomet Holdings Inc Stock (ZBH) Company Profile
Name
Zimmer Biomet Holdings Inc
Sector
Industry
Phone
(574) 267-6131
Address
345 EAST MAIN STREET, WARSAW, IN
Compare ZBH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZBH
Zimmer Biomet Holdings Inc
|
97.44 | 19.84B | 7.68B | 903.80M | 1.14B | 4.45 |
|
ABT
Abbott Laboratories
|
131.73 | 218.91B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
95.05 | 139.37B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
348.12 | 134.90B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
83.37 | 106.90B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
70.60 | 41.45B | 5.72B | 4.17B | 259.90M | 6.97 |
Zimmer Biomet Holdings Inc Stock (ZBH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-17-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-10-24 | Initiated | Wolfe Research | Peer Perform |
| Jul-01-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| May-30-24 | Initiated | Goldman | Neutral |
| May-21-24 | Upgrade | Argus | Hold → Buy |
| Jan-04-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-20-23 | Initiated | ROTH MKM | Neutral |
| Aug-28-23 | Upgrade | BTIG Research | Neutral → Buy |
| May-03-23 | Upgrade | BofA Securities | Underperform → Neutral |
| Apr-11-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Mar-31-23 | Upgrade | Jefferies | Underperform → Hold |
| Mar-29-23 | Initiated | UBS | Sell |
| Mar-10-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-09-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jan-05-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jan-03-23 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-23-22 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Oct-18-22 | Initiated | Barclays | Underweight |
| Oct-12-22 | Initiated | Jefferies | Underperform |
| May-27-22 | Downgrade | Needham | Buy → Hold |
| Apr-13-22 | Downgrade | Truist | Buy → Hold |
| Apr-01-22 | Downgrade | Citigroup | Buy → Neutral |
| Mar-02-22 | Resumed | BofA Securities | Underperform |
| Mar-02-22 | Downgrade | Loop Capital | Buy → Hold |
| Feb-08-22 | Downgrade | Canaccord Genuity | Buy → Hold |
| Feb-08-22 | Reiterated | Citigroup | Buy |
| Feb-08-22 | Reiterated | Deutsche Bank | Hold |
| Feb-08-22 | Reiterated | JMP Securities | Mkt Outperform |
| Feb-08-22 | Reiterated | JP Morgan | Neutral |
| Feb-08-22 | Reiterated | RBC Capital Mkts | Sector Perform |
| Feb-08-22 | Reiterated | Stifel | Buy |
| Feb-08-22 | Reiterated | Truist | Buy |
| Feb-08-22 | Reiterated | UBS | Neutral |
| Feb-08-22 | Reiterated | Wells Fargo | Underweight |
| Feb-02-22 | Downgrade | UBS | Buy → Neutral |
| Jan-19-22 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| Jan-10-22 | Downgrade | Mizuho | Buy → Neutral |
| Jan-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-04-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-10-21 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-09-21 | Downgrade | Needham | Strong Buy → Buy |
| Dec-07-21 | Initiated | Loop Capital | Buy |
| Nov-23-21 | Downgrade | Argus | Buy → Hold |
| Sep-14-21 | Resumed | Raymond James | Mkt Perform |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-09-21 | Upgrade | Northland Capital | Market Perform → Outperform |
| Jan-04-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-18-20 | Reiterated | Needham | Strong Buy |
| Oct-20-20 | Initiated | Northland Capital | Market Perform |
| Sep-11-20 | Initiated | Wolfe Research | Outperform |
| Aug-05-20 | Reiterated | Needham | Strong Buy |
| Apr-28-20 | Downgrade | Guggenheim | Buy → Neutral |
| Apr-09-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Apr-07-20 | Reiterated | Needham | Strong Buy |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Buy |
| Jan-08-20 | Initiated | SunTrust | Buy |
| Jan-07-20 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jan-07-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-04-19 | Upgrade | Raymond James | Outperform → Strong Buy |
| Oct-07-19 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-18-19 | Upgrade | Canaccord Genuity | Hold → Buy |
| Aug-12-19 | Upgrade | Argus | Hold → Buy |
| Jul-30-19 | Upgrade | Barclays | Underweight → Equal Weight |
| Jul-29-19 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jun-11-19 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Apr-24-19 | Upgrade | Needham | Buy → Strong Buy |
View All
Zimmer Biomet Holdings Inc Stock (ZBH) Latest News
What to Expect From Zimmer Biomet's Next Quarterly Earnings Report - MSN
Zimmer Biomet to Report Q1 Earnings: Here's What to Expect - TradingView
Zimmer acquires Paragon 28 in $1.2bn deal - Yahoo Finance
Is Zimmer Biomet Holdings, Inc. (ZBH) The Top Falling Stock with Unusual Volume? - Insider Monkey
Zimmer Biomet Holdings (ZBH) Completes Merger with Paragon 28 - GuruFocus
Paragon 28 concludes merger with Zimmer Biomet subsidiary By Investing.com - Investing.com South Africa
Paragon 28 concludes merger with Zimmer Biomet subsidiary - Investing.com
Zimmer Biomet completes Paragon 28 acquisition - MassDevice
What To Expect From Zimmer Biomet's Next Quarterly Earnings Report - Barchart.com
Zimmer Biomet Closes Paragon 28 Acquisition - marketscreener.com
Zimmer Biomet Completes Acquisition of Paragon 28 | ZBH Stock News - GuruFocus
Zimmer Biomet Completes Acquisition Of Paragon 28 - marketscreener.com
Zimmer Biomet Completes Acquisition of Paragon 28 - PR Newswire
Knee Replacement Market Detailed In New Research Report 2025 | - openPR.com
Maxillofacial surgery Market Projected To Witness Substantial - openPR.com
Bone Replacement Products Market Projected To Witness - openPR.com
Zimmer Biomet Hits 34th 52-Week Low: Value Play Or Value Trap? - Barchart.com
Zimmer Biomet stock touches 52-week low at $97.62 By Investing.com - Investing.com Canada
Zimmer Biomet Holdings Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Zimmer Biomet stock touches 52-week low at $97.62 - Investing.com
Stocks Edge Up On Strong Bank Earnings, Netflix Soars, Dollar Rebounds: What's Driving Markets Tuesday? - Benzinga
Zimmer Biomet (ZBH) Receives Price Target Boost Amid MedTech Sec - GuruFocus
Is the Market Bullish or Bearish on Zimmer Biomet Holdings? - Benzinga
Zimmer Biomet Holdings (NYSE:ZBH) Proposes Officer Exculpation Amendment at Upcoming Shareholder Meeting - Yahoo
SEC Form DEFA14A filed by Zimmer Biomet Holdings Inc. - Quantisnow
Zimmer Biomet granted CE Mark for RibFix Advantage Fixation System - MSN
Price Over Earnings Overview: Zimmer Biomet HoldingsZimmer Biomet Holdings (NYSE:ZBH) - Benzinga
Zimmer Biomet (ZBH): Buy, Sell, or Hold Post Q4 Earnings? - Yahoo Finance
Zimmer Biomet (ZBH): Buy, Sell, Or Hold Post Q4 Earnings? - Barchart.com
Zimmer Biomet Announces Webcast and Conference Call of First Qua - GuruFocus
Zimmer Biomet Announces Webcast and Conference Call of First Quarter 2025 Financial Results - The Malaysian Reserve
Zimmer Biomet First Quarter Earnings: Key Financial Results Coming May 5 - Stock Titan
Indo-Asian News Service - Indo-Asian News Service (IANS)
An Intrinsic Calculation For Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Suggests It's 39% Undervalued - simplywall.st
ZBH Stock to Gain From Volume Growth Amid Rising Costs - TradingView
Medical Device Industry: Swept Up in the Tariffs, Diabetes Device Makers Bear the Brunt - Morningstar
Evercore ISI Adjusts Zimmer Biomet Holdings' Price Target to $116 From 110, Maintains In Line Rating - MarketScreener
Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Purchased by UniSuper Management Pty Ltd - MarketBeat
Zimmer Biomet Gets CE Mark Approval for RibFix Advantage Fixation System - MarketScreener
Zimmer Biomet wins CE Mark for RibFix Advantage (ZBH:NYSE) - Seeking Alpha
Zimmer Biomet wins CE mark for rib fixation system - MassDevice
Zimmer Biomet Receives CE Mark Approval For Ribfix Advantage® Fixation System - MarketScreener
Zimmer Biomet Receives CE Mark Approval for RibFix Advantage® Fixation System – Company Announcement - Financial Times
Providence Capital Advisors LLC Buys 2,800 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) - MarketBeat
Zimmer Biomet Holdings Inc. stock underperforms Monday when compared to competitors despite daily gains - MarketWatch
Zimmer Biomet Holdings (NYSE:ZBH) Might Have The Makings Of A Multi-Bagger - Yahoo Finance
Corebridge Financial Inc. Lowers Stock Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) - MarketBeat
Zimmer Biomet Stock Price | ZBH Stock Quote, News, and History - markets.businessinsider.com
Just Three Days Till Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Will Be Trading Ex-Dividend - simplywall.st
Ex-Dividend Reminder: PG&E, Zimmer Biomet Holdings and Ensign Group - Nasdaq
Goldman Sachs Adjusts PT on Zimmer Biomet Holdings to $120 From $115, Maintains Neutral Rating - MarketScreener
Zimmer Biomet Holdings Inc Stock (ZBH) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):